<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01371201</url>
  </required_header>
  <id_info>
    <org_study_id>IGR2010/1715</org_study_id>
    <secondary_id>2010-024621-20</secondary_id>
    <secondary_id>MSI/A110356-31</secondary_id>
    <nct_id>NCT01371201</nct_id>
  </id_info>
  <brief_title>First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma</brief_title>
  <acronym>FIRSTMAPPP</acronym>
  <official_title>First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ENSAT-CANCER European Network for the Study of Adrenal Tumours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The FIRSTMAPPP study is a randomized, double-blind, phase II, international, multicenter&#xD;
      study which aims to determine the efficacy of Sunitinib on the progression-free survival at&#xD;
      12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated&#xD;
      with sunitinib at a starting dose of 37.5 mg daily (continuous dosing).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      To determine the efficacy of Sunitinib on the progression-free survival at 12 months in&#xD;
      subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib&#xD;
      at a starting dose of 37.5 mg daily (continuous dosing).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
        -  To determine overall survival and progression free survival.&#xD;
&#xD;
        -  To determine time to progression.&#xD;
&#xD;
        -  To determine objective response rate at one year.&#xD;
&#xD;
        -  To determine time to and duration of tumor response.&#xD;
&#xD;
        -  To assess safety profile including a dedicated cardiovascular management (home-blood&#xD;
           pressure monitoring, ECG and echocardiography).&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      -Identification of predictors of response as well as surrogate markers of overall survival is&#xD;
      anticipated&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Progression will be assessed by RECIST 1.1 performed every 3 months (centralized imaging)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rates (ORR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DR)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Time to Progression (TTP)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events assessed using NCI -CTC V4 criteria</measure>
    <time_frame>12 months</time_frame>
    <description>Number and description of adverse events and number of patients with adverse events according to NCI -CTC V4 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with cardiovascular toxicity tolerance assessed by specific organisation for blood pressure monitoring</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiovascular tolerance will be assessed by specific organisation for blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Pain evaluation on the Visual Analog Scale</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL)</condition>
  <arm_group>
    <arm_group_label>Sunitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sunitinib 37.5 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 37.5 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>sunitinib 37.5 mg per day</description>
    <arm_group_label>Sunitinib</arm_group_label>
    <other_name>Sutent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 37.5 mg per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of malignant PPGL, based on imaging or biopsy evidence of metastases in&#xD;
             liver, bones, lungs and or lymph nodes, combined with at least one of two further&#xD;
             confirmatory diagnoses: 1. diagnosis of PPGL from histopathological review of resected&#xD;
             or biopsied tissue performed by a skilled pathologist (centralized review will be&#xD;
             performed in all cases either before enrolment in case of any doubt or during the&#xD;
             study); or 2. in patients where tumor tissue is unavailable for formal pathological&#xD;
             review, from combined biochemical and functional imaging evidence of PPGL (e.g., MIBG&#xD;
             scintigraphy combined with consistently and highly elevated plasma or urine levels of&#xD;
             metanephrines).&#xD;
&#xD;
          -  Metastatic disease not amenable to surgical resection&#xD;
&#xD;
          -  Pre-treated or not&#xD;
&#xD;
          -  Whatever the genetic status (sporadic or inherited)&#xD;
&#xD;
          -  Evaluable disease according to RECIST 1.1 criteria&#xD;
&#xD;
          -  Progressing disease within 18 months at imaging prior to randomization according to&#xD;
             RECIST. The recent scan indicating progression may be used as the screening scan if&#xD;
             within 28 days of randomization&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 6 months as prognosticated by the physician&#xD;
&#xD;
          -  Age ≥18 years, no superior limit&#xD;
&#xD;
          -  Adequate bone marrow reserve (Hb &gt; 8, neutrophils ≥ 1500/mm³ and platelets&#xD;
             ≥80.000/mm³)&#xD;
&#xD;
          -  Effective contraception in pre-menopausal female and male patients&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Patient´s signed written informed consent&#xD;
&#xD;
          -  Ability to comply with the protocol procedures&#xD;
&#xD;
          -  Ability to take oral medication&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Large or small cell-poorly differentiated neuroendocrine carcinoma according to WHO&#xD;
             2000 classification&#xD;
&#xD;
          -  History of prior malignancy, except for cured non-melanoma skin cancer, cured in situ&#xD;
             cervical carcinoma, or other treated malignancies with no evidence of disease for at&#xD;
             least three years.&#xD;
&#xD;
          -  Severe renal (GFR &lt;30ml/mn or nephrotic syndrome) or hepatic insufficiency (ALT / AST&#xD;
             &gt; 2.5 x ULN or ALT/AST &gt;5 x ULN if liver function abnormalities are due to the&#xD;
             underlying malignancy and/or total serum bilirubin &gt; 2.5 x ULN)&#xD;
&#xD;
          -  Patients with cardiac events within the previous 12 months, such as myocardial&#xD;
             infarction (including severe/unstable angina pectoris), coronary/peripheral artery&#xD;
             bypass graft, revascularization procedure symptomatic congestive heart failure (CHF,&#xD;
             ejection fraction &lt;45%), ), uncontrolled cardiac arrhythmia, clinically significant&#xD;
             bradycardia, cerebrovascular accident or transient ischemic attack, or pulmonary&#xD;
             embolism&#xD;
&#xD;
          -  Hypertension that cannot be controlled despite medications (&gt;=160/95 mmHg despite&#xD;
             optimal medical therapy)&#xD;
&#xD;
          -  Abnormal cardiac function with 12 lead ECG. Ongoing cardiac dysrhythmias of NCI CTC&#xD;
             grade &gt;=2, atrial fibrillation of any grade, or prolongation of the QTc interval to&#xD;
             &gt;470 msec for males or &gt;480 msec for females.&#xD;
&#xD;
          -  Brain metastases (exception if stable and asymptomatic for more than 3 months)&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Previous treatment with the drug under study. Prior systemic treatment with any&#xD;
             tyrosine kinase inhibitors or anti VEGF angiogenic inhibitors.&#xD;
&#xD;
          -  Current treatment with another investigational drug.&#xD;
&#xD;
          -  Treatment with potent CYP3A4 inhibitors and inducers within 7 and 12 days,&#xD;
             respectively prior to study drug administration&#xD;
&#xD;
          -  Concomitant treatment with therapeutic doses of anticoagulants. Low dose warfarin&#xD;
             (Coumadin) up to 2 mg PO daily for deep vein thrombosis prophylaxis is allowed as well&#xD;
             as heparin-based anticoagulation&#xD;
&#xD;
          -  Prior treatments with chemotherapy, immunotherapy, somatostatine analog therapy drug ,&#xD;
             thoracic radiotherapy within 4 weeks prior to inclusion&#xD;
&#xD;
          -  Major surgery for any cause or local radiotherapy within one month prior to visit 1&#xD;
&#xD;
          -  Liver embolisation therapy within the last 3 months prior visit 1 except if&#xD;
             progression is demonstrated and embolised lesion not used as targets&#xD;
&#xD;
          -  Unrecovered toxicity from any kind of therapy&#xD;
&#xD;
          -  Active or suspected acute or chronic uncontrolled disease that would impart, in the&#xD;
             judgment of the investigator, excess risk associated with study participation or study&#xD;
             drug administration, or which, in the judgment of the investigator, would make the&#xD;
             patient inappropriate for entry into this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Baudin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institut de Cancérologie Gustave roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Baudin, MD</last_name>
      <email>eric.baudin@igr.fr</email>
    </contact>
    <investigator>
      <last_name>Eric Baudin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Schlumberger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Leboulleux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile Chougnet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin FASSNACHT, MD</last_name>
      <phone>0931-201-39021</phone>
    </contact>
    <investigator>
      <last_name>Martin FASSNACHT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giusepe OPOCHER, MD</last_name>
      <phone>0498215503</phone>
      <phone_ext>+39</phone_ext>
    </contact>
    <investigator>
      <last_name>Giusepe OPOCHER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <state>GA</state>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henry TIMMERS, MD</last_name>
      <phone>0243614599</phone>
      <phone_ext>+31</phone_ext>
    </contact>
    <investigator>
      <last_name>Henry TIMMERS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>http://www.igr.fr/</url>
    <description>Sponsor website</description>
  </link>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>June 9, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

